Cantor

Epic Bio to Participate in a Fireside Chat at the Cantor Virtual Muscular Dystrophy Symposium

Retrieved on: 
Monday, April 1, 2024
Patient, SAN, Cantor

SOUTH SAN FRANCISCO, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Epic Bio , a leading epigenetic editing company that plans to dose its first patients later this year, today announced that Amber Salzman, Ph.D., chief executive officer, will participate in a fireside chat at the Cantor Virtual Muscular Dystrophy Symposium at 9:40 a.m. PT, Tuesday, April 2, 2024.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Epic Bio , a leading epigenetic editing company that plans to dose its first patients later this year, today announced that Amber Salzman, Ph.D., chief executive officer, will participate in a fireside chat at the Cantor Virtual Muscular Dystrophy Symposium at 9:40 a.m. PT, Tuesday, April 2, 2024.
  • Institutional investors should contact their Cantor representatives for additional information.

Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering

Retrieved on: 
Friday, March 22, 2024
Health, Neurology, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, AAV, Sangamo Therapeutics, Form, Telephone, Sale, Attention, Security (finance), Prospectus, Form S-3, Capital market, Cantor, Broadridge Financial Solutions, Therapy, Barclays

The combined offering price of each share of common stock and accompanying warrant is $0.84, priced at-the-market under Nasdaq rules.

Key Points: 
  • The combined offering price of each share of common stock and accompanying warrant is $0.84, priced at-the-market under Nasdaq rules.
  • The combined offering price of each pre-funded warrant and accompanying warrant is $0.83.
  • The gross proceeds to Sangamo from the offering, before deducting the placement agents’ fees and other offering expenses, are expected to be approximately $24.0 million.
  • The offering is expected to close on or about March 26, 2024, subject to customary closing conditions.

Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Retrieved on: 
Tuesday, March 5, 2024
Lexington Avenue, Telephone, Cantor, Sale, Exercise, Form, State Street, SVB Securities, Therapy, Guggenheim Partners, Security (finance)

HAMPTON, N.J., March 05, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced the closing of its previously announced underwritten public offering of 9,798,000 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase an additional 1,278,000 shares of common stock at a public offering price of $47.00 per share.

Key Points: 
  • HAMPTON, N.J., March 05, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced the closing of its previously announced underwritten public offering of 9,798,000 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase an additional 1,278,000 shares of common stock at a public offering price of $47.00 per share.
  • All of the shares sold in the offering were sold by Celldex.
  • The gross proceeds to Celldex from this offering were approximately $460.5 million, excluding underwriting discounts and commissions and other offering-related expenses.
  • Leerink Partners, TD Cowen, Guggenheim Securities and Cantor acted as the joint bookrunning managers for the offering.

Humacyte, Inc. Announces Pricing of $40.2 Million Public Offering of Common Stock

Retrieved on: 
Friday, March 1, 2024
Attention, Lexington Avenue, Regenerative medicine, Prospectus, Capital market, Telephone, Food, Cantor, Sale, Form, Security (finance), HUMA

The aggregate gross proceeds from this offering are expected to be $40.2 million, before deducting underwriting discounts and commissions and other offering expenses payable by Humacyte.

Key Points: 
  • The aggregate gross proceeds from this offering are expected to be $40.2 million, before deducting underwriting discounts and commissions and other offering expenses payable by Humacyte.
  • The closing of the offering is expected to occur on or about March 5, 2024, subject to the satisfaction of customary closing conditions.
  • In addition, Humacyte has granted the underwriters an option for a period of 30 days to purchase up to an additional 2,010,000 shares of Humacyte’s common stock at the public offering price, less underwriting discounts and commissions.
  • All of the shares of common stock are being sold by Humacyte.

Celldex Therapeutics Announces Pricing of Upsized $400 Million Public Offering of Common Stock

Retrieved on: 
Friday, March 1, 2024
Lexington Avenue, Prospectus, Telephone, Cantor, Sale, Exercise, Form, State Street, SVB Securities, Therapy, S-3, Guggenheim Partners

HAMPTON, N.J., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced the pricing of an upsized underwritten public offering of 8,520,000 shares of its common stock at a public offering price of $47.00 per share.

Key Points: 
  • HAMPTON, N.J., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced the pricing of an upsized underwritten public offering of 8,520,000 shares of its common stock at a public offering price of $47.00 per share.
  • All of the shares to be sold in the offering are to be sold by Celldex.
  • In connection with the offering, Celldex has granted the underwriters a 30-day option to purchase up to an additional 1,278,000 shares of common stock at the public offering price, less underwriting discounts and commissions.
  • The Company expects to receive gross proceeds from the offering, excluding the exercise of the underwriters’ option, if any, of approximately $400.4 million, excluding underwriting discounts and commissions and other offering-related expenses.

Humacyte, Inc. Announces Proposed Public Offering of Common Stock

Retrieved on: 
Thursday, February 29, 2024
Attention, Lexington Avenue, Regenerative medicine, Prospectus, Capital market, Telephone, Food, Cantor, Sale, Form, Security (finance), HUMA, Pharmaceutical industry

DURHAM, N.C., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today announced that it has commenced an underwritten public offering of its common stock.

Key Points: 
  • DURHAM, N.C., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today announced that it has commenced an underwritten public offering of its common stock.
  • In addition, Humacyte intends to grant the underwriters an option for a period of 30 days to purchase up to an additional 15% of the number of shares of common stock sold in connection with the offering.
  • TD Cowen and Cantor are acting as joint book-running managers for the offering.
  • The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Mind Medicine (MindMed) Inc. Announces Pricing of Underwritten Offering of Common Shares and Concurrent Private Placement

Retrieved on: 
Thursday, March 7, 2024
Research, Mental Health, Neurology, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, Janus, Attention, Prospectus, Medicine, Capital market, MindMed, Telephone, RBC Capital Markets, File, Cantor, Sale, Form, Richard Driehaus, State Street, SVB Securities, Security (finance)

In addition, the Company has entered into share purchase agreements for a concurrent private placement of 12,500,000 common shares at a price of $6.00 per common share.

Key Points: 
  • In addition, the Company has entered into share purchase agreements for a concurrent private placement of 12,500,000 common shares at a price of $6.00 per common share.
  • Gross proceeds to MindMed from the underwritten offering and concurrent private placement, before deducting underwriting commissions, placement agent fees and other offering-related expenses, are expected to be approximately $175 million.
  • Leerink Partners and Cantor are acting as joint bookrunning managers for the underwritten offering and placement agents for the private placement.
  • RBC Capital Markets is acting as lead manager for the underwritten offering and placement agent for the private placement.

Fannie Mae Prices $751 Million Connecticut Avenue Securities (CAS) REMIC Deal

Retrieved on: 
Thursday, March 7, 2024
Fannie Mae, News, Cantor, Disclosure, Wells Fargo, Morgan Stanley, CAS, StoneX Group Inc., BofA Securities, Bank of America, Minority, Citigroup, Bank

StoneX Financial Inc. ("StoneX") is the co-lead manager and joint bookrunner.

Key Points: 
  • StoneX Financial Inc. ("StoneX") is the co-lead manager and joint bookrunner.
  • Co-managers are BofA Securities, Inc. ("BofA"), Cantor Fitzgerald & Co. ("Cantor"), Citigroup Global Markets Inc. ("Citigroup"), and Morgan Stanley & Co, LLC ("Morgan Stanley").
  • To promote transparency and to help credit investors evaluate our securities and the CAS program, Fannie Mae provides ongoing, robust disclosure data, as well as access to news, resources, and analytics through its credit risk transfer webpages .
  • In addition to our flagship CAS program, Fannie Mae continues to transfer mortgage credit risk through its Credit Insurance Risk Transfer™ (CIRT™) reinsurance program.

National Geographic Society Launches the Wildlife Intelligence Project

Retrieved on: 
Wednesday, February 21, 2024
Ecology, Bee, Dolphin, Neuroscience, Research, Intelligence, Lab, Culture, Animal, Cantor, Oregon State University, Physiology, Nature, Empathy, University, Society, Behavior, National Geographic Society, Cooperation, Royal Geographical Society, Cognition, Chimpanzee, Templeton Prize, UN, Felicity, National Geographic, Human, Environment, Hunting

WASHINGTON, Feb. 21, 2024 /PRNewswire/ -- The National Geographic Society announced today the launch of the Wildlife Intelligence Project, an initiative that will fund and follow three National Geographic Explorers as they embark on animal cognition and behavior research that will potentially adapt how humans view, interact and connect with wildlife.

Key Points: 
  • Inspired by Dr. Jane Goodall and the Templeton Prize, the research initiative will support three National Geographic Explorers as they seek to uncover critical insights into animal behavior
    WASHINGTON, Feb. 21, 2024 /PRNewswire/ -- The National Geographic Society announced today the launch of the Wildlife Intelligence Project , an initiative that will fund and follow three National Geographic Explorers as they embark on animal cognition and behavior research that will potentially adapt how humans view, interact and connect with wildlife.
  • "We are proud to launch the Wildlife Intelligence Project and to support and empower the next generation of scientists committed to furthering Dr. Goodall's legacy of inspiring people to take action to protect the wonder of our world," said Ian Miller, Chief Scientist and Innovation Officer, National Geographic Society.
  • We are pleased to be partnering with the National Geographic Society on the Wildlife Intelligence Project and look forward to seeing what new insights we can gain."
  • The work being done by the recipients of the Wildlife Intelligence Project is essential to developing a better understanding of human-animal behavior and the healthy functioning of our planet.

KalVista Pharmaceuticals Announces Pricing of a $160.1 Million Public Offering of Common Stock and Pre-Funded Warrants

Retrieved on: 
Thursday, February 15, 2024
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Attention, Jefferies Group, Prospectus, Capital market, Suite, Telephone, Cantor, Sale, Montgomery Street, Form, State Street, SVB Securities, Madison Avenue, KALV, Needham & Company, Security (finance)

KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) (“KalVista”) today announced the pricing of its underwritten public offering of (i) 7,016,312 shares of its common stock at a price to the public of $15.25 per share and (ii) pre-funded warrants to purchase 3,483,688 shares of common stock in lieu of KalVista common stock to certain investors.

Key Points: 
  • KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) (“KalVista”) today announced the pricing of its underwritten public offering of (i) 7,016,312 shares of its common stock at a price to the public of $15.25 per share and (ii) pre-funded warrants to purchase 3,483,688 shares of common stock in lieu of KalVista common stock to certain investors.
  • The gross proceeds to KalVista from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by KalVista, are expected to be $160.1 million.
  • In addition, KalVista has granted the underwriters a 30-day option to purchase up to an additional 1,575,000 shares of common stock at the public offering price, less underwriting discounts and commissions.
  • All of the shares of common stock and pre-funded warrants are being offered by KalVista.